Therapeutic Area
-
Acute Kidney Injury (AKI) | Primary Research (KOL’s Insight) | Competitive Intelligence | Market Analytics & Forecast 2030
$6,500.00 – $19,500.00Select optionsGrowth of the incidence AKI population will contribute to increasing sales in the AKI therapy market over our forecast period. An estimated annual growth rate of 2.68% in the diagnosed incident AKI population across the major pharmaceutical markets will contribute to increasing AKI therapy sales. In 2019, there were approximately 1.95 million diagnosed cases of AKI in the major markets; we expect the number of cases will exceed 2.08 million in 2030 owing to changes in population demographics and increasing cases of AKI associated conditions such as sepsis-AKI, Cardiac surgery-associated AKI and others.The continuous involvement of supportive treatments including renal replacement therapies for the management of AKI patients will contribute to the the overall growth of the AKI therapy market. We forecast that total sales of the total care market will reach $5.2 billion by 2030. -
Acute Myeloid Leukemia (AML) -The Changing Landscape of Treatment in AML, Executive Deck 2020
$7,500.00 – $12,500.00Select optionsAcute myelogenous leukemia (AML) Disease Landscape provides comprehensive market intelligence with epidemiology, keen insight into current treatment paradigms, in-depth pipeline coverage ( ~ 470 unique industry-sponsored studies) and clinical trial landscape supported by detailed recent results (~ 96 trial’s results) from ASH 2019, ASCO 2020 and EHA 2020. The drugs are further classified according to the class of therapies: antibody drug conjugates, bispecific antibodies, tri-specific and monoclonal antibodies, CAR-T therapies & T cells therapies, vaccines, small molecules and others.
-
Acute Myeloid Leukemia (AML) -The Changing Landscape of Treatment in AML, Executive Deck 2020
$7,500.00 – $15,450.00Select optionsAcute myelogenous leukemia (AML) Disease Landscape provides comprehensive market intelligence with epidemiology, keen insight into current treatment paradigms, in-depth pipeline coverage ( ~ 470 unique industry-sponsored studies) and clinical trial landscape supported by detailed recent results (~ 96 trial’s results) from ASH 2019, ASCO 2020 and EHA 2020. The drugs are further classified according to the class of therapies: antibody drug conjugates, bispecific antibodies, tri-specific and monoclonal antibodies, CAR-T therapies & T cells therapies, vaccines, small molecules and others.
-
Adult Acute Lymphoblastic Leukemia (aALL) | Primary Research (KOL’s Insight) | Competitive Intelligence | Market Analytics & Forecast 2030
$6,500.00 – $19,500.00Select optionsAbout 60% of ALL adult patients relapse or are refractory to first-line therapy and a high unmet need continues to exist. CD19 CAR T candidate with compelling activity and safety profile and has the potential to change the standard of care as a curative therapy for r / r ALL. Sales of emerging therapies to treat adult Acute Lymphoblastic Leukemia (aALL) in the countries under study (United States, France, Germany, Italy, Spain, United Kingdom, and Japan) will experience high growth over the 2020-2030 study period, adding an estimated value to a total $1.2 billion market by 2030.
-
Adult Acute Lymphoblastic Leukemia (aALL) | Primary Research (KOL’s Insight) | Competitive Intelligence | Market Analytics & Forecast 2030
$9,750.00 – $19,500.00Select optionsAbout 60% of ALL adult patients relapse or are refractory to first-line therapy and a high unmet need continues to exist. CD19 CAR T candidate with compelling activity and safety profile and has the potential to change the standard of care as a curative therapy for r / r ALL. Sales of emerging therapies to treat adult Acute Lymphoblastic Leukemia (aALL) in the countries under study (United States, France, Germany, Italy, Spain, United Kingdom, and Japan) will experience high growth over the 2020-2030 study period, adding an estimated value to a total $1.2 billion market by 2030.
-
Allergic Conjuctivitis (AC) | Landscape & Forecast | Competitive Landscape & Forecast, 2020-2030
$5,250.00 – $15,750.00Select optionsThe Allergic Conjuctivitis (AC) report provides the detailed overview of the disease and exhaustive understanding of historical and forecasted epidemiology. It highlights the prevailing treatment patterns, potential upcoming drugs and also identifies better of the market opportunities by providing the historical and forecasted market revenue, sales trends, and drug uptake during the study period from 2019-2030.
-
Central Precocious Puberty | Primary Research (KOL’s Insight) | Competitive Intelligence | Market Analytics & Forecast 2030
$6,500.00 – $19,500.00Select optionsGrowth of the diagnosed CPP population will contribute to increasing sales in the CPP therapy market over our forecast period. An estimated annual growth rate of 0.12% in the diagnosed CPP population across the major pharmaceutical markets will contribute to increasing CPP therapy sales. In 2019, there were approximately xx diagnosed cases of CPP in the major markets; we expect the number of cases will exceed xx in 2030 owing to changes in population demographics and increasing awareness related to this rare disease.Strong Uptake of the 6-months Leuprolide acetate (Fensolvi) will be driven by the need for an alternative therapy for 3-months depot Leuprolide acetate and will contribute to the growth of the CPP market. We expect leuprolide acetate to be preferentially prescribed to patients. However, as physicians become more familiar with the agent, we expect Fensolvi to gain more patient share. The drug is forecasted to earn sales of $xx million in 2030 . -
Central Precocious Puberty | Primary Research (KOL’s Insight) | Competitive Intelligence | Market Analytics & Forecast 2030
$6,500.00 – $19,500.00Select optionsGrowth of the diagnosed CPP population will contribute to increasing sales in the CPP therapy market over our forecast period. An estimated annual growth rate of 0.12% in the diagnosed CPP population across the major pharmaceutical markets will contribute to increasing CPP therapy sales. In 2019, there were approximately xx diagnosed cases of CPP in the major markets; we expect the number of cases will exceed xx in 2030 owing to changes in population demographics and increasing awareness related to this rare disease.Strong Uptake of the 6-months Leuprolide acetate (Fensolvi) will be driven by the need for an alternative therapy for 3-months depot Leuprolide acetate and will contribute to the growth of the CPP market. We expect leuprolide acetate to be preferentially prescribed to patients. However, as physicians become more familiar with the agent, we expect Fensolvi to gain more patient share. The drug is forecasted to earn sales of $xx million in 2030 . -
Sale!
Chimeric Antigen Receptor (CAR-T) Cell Therapy – Market Opportunity, Pipeline & Competitive Intelligence 2020
$2,400.00 – $7,200.00Select optionsChimeric antigen receptor (CAR) T-cell therapy has generated a great amount of interest and have encouraged investors to support development in the field of adoptive cellular immunotherapy. Over the past couple of years, there has been rapid progress in the field. Researchers are refining the safety and efficacy profiles of CAR T cells with new concepts and technologies. These will be therapies that will address current challenges through mechanisms of superior efficacy, safety and delivery. -
Chronic Kidney Disease (CKD) | Primary Research (KOL’s Insight) | Competitive Intelligence | Market Analytics & Forecast 2030
$6,500.00 – $19,500.00Select optionsGrowth of the Prevalence CKD population will contribute to increasing sales in the CKD therapy market over our forecast period. An estimated annual growth rate of 0.4% in the Prevalent CKD population across the major pharmaceutical markets will contribute to increasing CKD therapy sales. In 2019, there were approximately 94 million prevalent cases of CKD in the major markets; we expect the number of cases will exceed 2.08 million in 2030 owing to changes in population demographics and increasing cases of CKD associated conditions such as anemia, hyperphosphatemia, secondary hyperthyroidism, diabetes kidney disease and cardiovascular patients group.The continuous involvement of supportive treatments including renal replacement therapies for the management of dialysis dependent CKD patients will contribute to the the overall growth of the CKD therapy market. We forecast that total sales of the total current RRTs market will reach $13 billion by 2030. -
Complex regional pain syndrome (CRPS)| Primary Research (KOL’s Insight) | Market Intelligence | Epidemiology & Market Forecast-2030
$6,500.00 – $19,500.00Select optionsComplex regional pain syndrome (CRPS) is a chronic pain condition characterized by spontaneous and evoked regional pain, usually starting in a distal extremity, which is disproportionate in magnitude or duration to the typical pain course after similar tissue trauma. Current treatment for CRPS requires a multidisciplinary approach involving patient education, physical and occupational therapy, psychiatry and pain medicine specialists, along with pharmacological and surgical interventions. Unfortunately, the current available treatment options are generally considered to be ineffective and one-dimensional, as they only treat part of the disease. Emerging therapies like Soticlestat (Takeda / Ovid Therapeutics and Lanicemine (AstraZeneca / Biohaven Pharmaceuticals) is expected to generate more market share than other emerging therapies and have the potential to overcome the treatment barrier.
-
Corticobasal Syndrome (CBS) | Primary Research (KOL’s Insight) | Market Intelligence | Epidemiology & Market Forecast-2030
$6,500.00 – $19,500.00Select optionsCorticobasal syndrome (CBS) is characterized by lowest clinical diagnostic accuracy, with the highest clinical presentation found in corticobasal degeneration (CBD). Current Corticobasal syndrome (CBS) treatment is limited to levodopa, commonly prescribed medication for the treatment of Parkinson’s disease. Thus, there is a huge unmet need for a medical treatment to improve the quality of life. Emerging therapies like Rho-kinase inhibitor- Fasudil (Woolsey Pharmaceuticals) have the potential to overcome the treatment barrier. Corticobasal syndrome market size will reflect high growth from 2025-2030 due to launch of Fausdil (Woolsey) in the market from 2025 year.